US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

241.79

+18.798.42%

Volume:399.31K

Turnover:94.23M

Market Cap:634.56M

PE:- -

High:242.94

Open:223.71

Low:222.88

Close:223.00

52wk High:341.93

52wk Low:102.35

Shares:2.62M

Float Shares:2.62M

Volume Ratio:1.51

T/O Rate:15.21%

Dividend:0.91

Dividend Rate:0.38%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Man Group PLC : Form 8.3 - Spire Healthcare Group Plc

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)

Humanwell Healthcare to Raise 3.35 Billion Yuan From Share Placement

MT Newswires Live

Hutchmed Lung-Cancer Fighting Drug Submitted to FDA for Approval

MT Newswires Live

Health Care Roundup: Market Talk

Ping An Healthcare to Renew Agreements with Ping An Life Insurance

MT Newswires Live

Symbiotec Gets U.S. FDA EIR With VAI Rating for Pithampur Plant

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA)

Buy Rating Backed by Strong Rare Liver Disease Franchise, Expanding Commercial Footprint, and Favorable Risk‑Reward at Mirum Pharmaceuticals

IHH Healthcare Says India Supreme Court Disposes of Fortis Forensic Audit Petition

MT Newswires Live

Epiminder sets virtual AGM as FDA‑cleared Minder EEG device gains clinical traction

Promisia moves to fast-track full ownership of Golden View Village

NeOnc Plans FDA End-of-Phase 1 Meeting for NEO212

SI-BONE Receives FDA 510(k) Approval for Spinal Fusion System

MT Newswires Live

Healthcare Stocks Rise to Start Week

Teva Reports FDA Approval for Degevma

MT Newswires Live

SI-Bone announces FDA 510(k) clearance of iFuse Granite Onyx System

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LABU/news?page=18"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":241.785,"timestamp":1791562865903,"preClose":223,"halted":0,"volume":399307,"delay":0,"changeRate":0.08423766816143496,"floatShares":2624500,"shares":2624500,"eps":0,"marketStatus":"Trading","change":18.785,"latestTime":"10-09 12:21:08 EDT","open":223.71,"high":242.9359,"low":222.88,"amount":94229927.32361999,"amplitude":0.089937,"askPrice":242.11,"askSize":40,"bidPrice":241.47,"bidSize":30,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":223,"sharesOutstanding":3074486,"nav":227.52,"aum":597123938.28,"dividendRate":0.003781,"bidAskSpread":0.003146,"preHourTrading":{"tag":"盘前","latestPrice":223.28,"preClose":223,"latestTime":"09:28 EDT","volume":2212,"amount":498293.87776,"timestamp":1791552512789,"change":0.28,"changeRate":0.001256,"amplitude":0.01487},"postHourTrading":{"tag":"盘后","latestPrice":223.66,"preClose":223,"latestTime":"19:57 EDT","volume":4124,"amount":918785.7173,"timestamp":1791503872443,"change":0.66,"changeRate":0.00296,"amplitude":0.008427},"volumeRatio":1.510292,"impliedVol":1.0126,"impliedVolPercentile":0.8725},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2624500,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.510292,"shares":2624500,"dividePrice":0.9143,"high":242.9359,"amplitude":0.089937,"preClose":223,"low":222.88,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":241.785,"committee":-0.142857,"eps":0,"divideRate":0.003781,"volume":399307,"delay":0,"ttmEps":0,"open":223.71,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":248.72,"twentyDayClose":261.3,"sixtyDayClose":254.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:18,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671218310","title":"Man Group PLC : Form 8.3 - Spire Healthcare Group Plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2671218310","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671218310?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:41","pubTimestamp":1790674860,"startTime":"0","endTime":"0","summary":"FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370567/0/en/man-group-plc-form-8-3-spire-healthcare-group-plc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","HCSG","XBI","BK4585","LU0128526141.USD","BK4137","BK4588","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671290718","title":"Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671290718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671290718?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:30","pubTimestamp":1790674217,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 4D Molecular Therapeutics (FDMT), Envista Holdings...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-envista-holdings-nvst-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-envista-holdings-nvst-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU2362541273.HKD","LU0882574055.USD","IE0034390439.USD","NVST","LU0823434583.USD","LU0320765992.SGD","LU0130103400.USD","LU0114720955.EUR","LU0477156797.USD","LU2089984988.USD","LU0130518102.USD","BBH","BK4082","LU2023250504.SGD","LU0029874061.USD","BK4137","LU1201861165.SGD","LU0648000940.SGD","XLV","IBB","BK4585","LU1974910355.USD","LU0058720904.USD","LU0823416689.USD","BK4588","BK4581","HCSG","LU0289739699.SGD","XBI","IE00B19Z6F94.USD","LU1917777945.USD","LU2362541513.USD","LU0128526141.USD","LU0109394709.USD","LU2362540622.SGD","LU2468319806.SGD","BK4139","FDMT","LU0823434740.USD","REGN","LABU","TBXU","IBBQ","LU0053666078.USD","LU2106854487.HKD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297786","title":"Humanwell Healthcare to Raise 3.35 Billion Yuan From Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297786","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671297786?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:10","pubTimestamp":1790673013,"startTime":"0","endTime":"0","summary":"Humanwell Healthcare  plans to raise up to 3.35 billion yuan from a share placement, according to a Shanghai bourse filing on Tuesday.The company will place shares to the pharmaceutical company's controlling shareholder, China Merchants Biomedicine.The proceeds will be used for the Yichang Renfu subsidiary project, the construction of a headquarters research institute and a manufacturing base for sexual health products, the development of a digital project and the supplementation of working capital.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0185","BK0028","600079","BK0070","BK4137","BK0096","XLV","LABU","BK0239","BK4581","LU0029874061.USD","BK4585","BK4588","HCSG","XBI","LU0128526141.USD","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292587","title":"Hutchmed Lung-Cancer Fighting Drug Submitted to FDA for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292587","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671292587?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:26","pubTimestamp":1790670412,"startTime":"0","endTime":"0","summary":"HUTCHMED said Tuesday that partner AstraZeneca  has submitted a New Drug Application to the US Food and Drug Administration for the lung-cancer fighting drugs Orpathys plus Tagrisso.The drug combination treats metastatic non-small cell lung cancers, the tumors of which have over-expression or amplification of proteins on their surfaces, in patients who had disease progression on or after an epidermal growth factor receptor tyrosine kinase inhibitor therapy, said Hutchmed.The drug combination is an oral, biomarker-directed, chemotherapy-free treatment for non-small cell lung cancers, the validity of which is supported by Saffron, a completed global phase III trial, said Hutchmed.The Saffron trial showed the drug combination demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doublet platinum-based chemotherapy in patients who progressed on treatment with Tagrisso alone, said Hutchmed.The Orpathys pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","LU1829250122.USD","LU2462157665.USD","LU0708994859.HKD","LU0889565916.HKD","LU2468319806.SGD","LU2417539215.USD","LU0058720904.USD","LU2237443622.USD","LU0289739699.SGD","LU0128525929.USD","LU0432979614.USD","LU2237443382.USD","BK4568","LU2237443895.HKD","LU2237443978.SGD","LU2456880835.USD","HCM","LU1267930573.SGD","BK4531","LU2236285917.USD","LU0029864427.USD","IE00B3T34201.USD","AZNH","BK4588","LU0109394709.USD","BK4585","AZN","LU2089984988.USD","BK4007","LU0320765992.SGD","LU0310800379.SGD","LU2237443465.HKD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292370","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671292370?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:20","pubTimestamp":1790670000,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0712 GMT - Eurofins Scientific's 2027 target of an improvement i","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4220","LABU","XLV","BK4103","XBI","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671295721","title":"Ping An Healthcare to Renew Agreements with Ping An Life Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2671295721","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671295721?lang=en_us&edition=fundamental","pubTime":"2026-09-29 14:27","pubTimestamp":1790663256,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology Company  said its board has proposed to renew certain agreements with its parent-affiliated company, Ping An Life Insurance Co. of China, originally signed in 2023, according to a Monday Hong Kong bourse filing.The healthcare platform operator said it will issue a circular with final details of the agreement, including an independent board committee's recommendation and financial advisor Gram Capital's opinion on the proposed renewal, on or around Nov. 9.Ping An Healthcare's shares were last up 5% in Tuesday afternoon trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1219","BK4137","LU0029874061.USD","BK4588","BK4581","PAImain","LABU","BK1142","BK1515","BK4585","HCSG","BK1247","BK1615","01833","LU0128526141.USD","XLV","BK1571","BK1617","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671629393","title":"Symbiotec Gets U.S. FDA EIR With VAI Rating for Pithampur Plant","url":"https://stock-news.laohu8.com/highlight/detail?id=2671629393","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671629393?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:32","pubTimestamp":1790659978,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Symbiotec Pharmalab Limited ( ($IN:SYMBIOTEC) ). Symbiotec Pharmalab Limited has received an Establishment Insp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/symbiotec-gets-u-s-fda-eir-with-vai-rating-for-pithampur-plant?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/symbiotec-gets-u-s-fda-eir-with-vai-rating-for-pithampur-plant?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VAI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671829804","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671829804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671829804?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:00","pubTimestamp":1790658033,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inventiva (IVA) and Moderna (MRNA). Inventiva (IVA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","LU0128526141.USD","LU0029874061.USD","BK4139","MRNX","HCSG","MRNY","BK4534","BK4588","WDNA","BK4548","BK4551","XLV","LGHT","BK4581","BK4585","IDNA","BK4533","GNOM","BK4568","MRNA","BK4137","LABU","BK4501","BK4532","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298192","title":"Buy Rating Backed by Strong Rare Liver Disease Franchise, Expanding Commercial Footprint, and Favorable Risk‑Reward at Mirum Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671298192?lang=en_us&edition=fundamental","pubTime":"2026-09-29 12:55","pubTimestamp":1790657719,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Schwartz from Leerink Partne...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-backed-by-strong-rare-liver-disease-franchise-expanding-commercial-footprint-and-favorable-riskreward-at-mirum-pharmaceuticals-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-backed-by-strong-rare-liver-disease-franchise-expanding-commercial-footprint-and-favorable-riskreward-at-mirum-pharmaceuticals-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","XBI","XLV","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298622","title":"IHH Healthcare Says India Supreme Court Disposes of Fortis Forensic Audit Petition","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298622","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671298622?lang=en_us&edition=fundamental","pubTime":"2026-09-29 12:54","pubTimestamp":1790657698,"startTime":"0","endTime":"0","summary":"IHH Healthcare  said India's Supreme Court on Sept. 25, Friday, disposed of Fortis Healthcare's  Special Leave Petition challenging a Delhi High Court order requiring a forensic audit of Fortis and certain observations concerning the company.The company's unit, Northern TK Venture, acquired a 31% stake in Fortis in 2018 through a competitive bidding process, involving a 40 billion rupees preferential allotment and a mandatory tender offer to public shareholders.IHH said the acquisition was completed months after former Fortis promoters Malvinder and Shivinder Singh had resigned from the company's board in March 2018. It said no secondary shares were acquired from them and no payments were made to them, adding that it was not a party to the dispute between Daiichi Sankyo and the former promoters.The healthcare company said it will cooperate fully with the forensic audit and remains committed to Fortis, with plans to increase its stake to 51% over the next three to five years.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNDmain","BK6511","HCSG","LU0128526141.USD","Q0F.SI","BK6092","BK4581","BK4137","LABU","BK4585","XBI","XLV","LU0029874061.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298394","title":"Epiminder sets virtual AGM as FDA‑cleared Minder EEG device gains clinical traction","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671298394?lang=en_us&edition=fundamental","pubTime":"2026-09-29 12:27","pubTimestamp":1790656036,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Epiminder Ltd. ( ($AU:EPI) ). Epiminder Limited has called its Annual General Meeting for 30 October 2026, sche...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/epiminder-sets-virtual-agm-as-fdacleared-minder-eeg-device-gains-clinical-traction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/epiminder-sets-virtual-agm-as-fdacleared-minder-eeg-device-gains-clinical-traction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPI","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671260263","title":"Promisia moves to fast-track full ownership of Golden View Village","url":"https://stock-news.laohu8.com/highlight/detail?id=2671260263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671260263?lang=en_us&edition=fundamental","pubTime":"2026-09-29 12:18","pubTimestamp":1790655481,"startTime":"0","endTime":"0","summary":"Promisia Healthcare Limited ( ($NZ:PHL) ) has issued an update. Promisia Healthcare has secured an option to accelerate its acquisition of the Gold...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/promisia-moves-to-fast-track-full-ownership-of-golden-view-village?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/promisia-moves-to-fast-track-full-ownership-of-golden-view-village?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["518880","SGCmain","159934","NUGT","GDX","DUST","BK4585","IAU","BK4588","LABU","XLV","SGUmain","BK4581","GCmain","MGCmain","GLD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671268127","title":"NeOnc Plans FDA End-of-Phase 1 Meeting for NEO212","url":"https://stock-news.laohu8.com/highlight/detail?id=2671268127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671268127?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:28","pubTimestamp":1790630903,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings, Inc. ( ($NTHI) ) just unveiled an update. NeOnc Technologies announced on September 28, 2026, that it is scheduled to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neonc-plans-fda-end-of-phase-1-meeting-for-neo212?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neonc-plans-fda-end-of-phase-1-meeting-for-neo212?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671686112","title":"SI-BONE Receives FDA 510(k) Approval for Spinal Fusion System","url":"https://stock-news.laohu8.com/highlight/detail?id=2671686112","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671686112?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:24","pubTimestamp":1790630642,"startTime":"0","endTime":"0","summary":"SI-BONE  said late Monday it received a 510 clearance from the US Food and Drug Administration for the iFuse Granite Onyx system to treat screw loosening in spinal fusion procedures, especially in patients with low bone density.The system allows for rapid osseointegration and lower micromotion to aim for early fixation and reduced screw loosening, according to a statement.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","SIBN","LABU","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671686982","title":"Healthcare Stocks Rise to Start Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2671686982","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671686982?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:19","pubTimestamp":1790630340,"startTime":"0","endTime":"0","summary":"Shares of health care companies were among the few winning sectors Monday as the broader market posted losses.Roche Holding said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn't hit internal targets. The Swiss drugmaker said it returned rights to the medicine, emugrobart, to its majority-owned business Chugai Pharmaceutical  which originally discovered the drug and licensed it to Roche. \"We have made the decision to discontinue development,\" Roche's pharmaceuticals chief executive, Teresa Graham, said at an event with investors in London on Monday. \"We are returning that molecule to Chugai, and Chugai is looking to further development in [spinal muscular atrophy] as well as considering potential outlicensing opportunities.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","XBI","XLV","HCSG","BK4585","BK4581","LU0128526141.USD","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671250803","title":"Teva Reports FDA Approval for Degevma","url":"https://stock-news.laohu8.com/highlight/detail?id=2671250803","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671250803?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:25","pubTimestamp":1790627151,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said late Monday the US Food and Drug Administration has approved Degevma as a biosimilar to Xgeva.Degevma is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, it said.The drug is also indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy, Teva said.Teva said it expects to launch Degevma and Ponlimsi in the US in the coming months. Ponlimsi was approved in March.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2324357040.USD","BK4557","BK4559","LU1983299246.USD","BK4596","BK4584","LABU","BK4566","BK4007","BK4585","TEVA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671250198","title":"SI-Bone announces FDA 510(k) clearance of iFuse Granite Onyx System","url":"https://stock-news.laohu8.com/highlight/detail?id=2671250198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671250198?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:15","pubTimestamp":1790626541,"startTime":"0","endTime":"0","summary":"SI-Bone (SIBN) announced FDA 510(k) clearance for the iFuse Granite Onyx System. This is SI-Bone’s first product addressing the problem of compromi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/si-bone-announces-fda-510k-clearance-of-ifuse-granite-onyx-system-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/si-bone-announces-fda-510k-clearance-of-ifuse-granite-onyx-system-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SIBN","BK4588","LABU","BK4082","ONYXU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671505722","title":"SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671505722","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671505722?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:09","pubTimestamp":1790626140,"startTime":"0","endTime":"0","summary":"FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density boneSANTA CLARA, Calif., Sept.  28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3370259/0/en/si-bone-receives-fda-510-k-clearance-for-ifuse-granite-onyx-extending-its-compromised-bone-franchise-beyond-the-pelvis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BDD","ONYXU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MRNY","PINK","IYH","TEVA","XLVX","SYNB","NVIB","RSPH","LFSC","BK4559","MEDI","GDOC","BK4557","BK4566","BK4588","BBP","BMED","GNMX","BK4007","IBB","LU2324357040.USD","IDNA","IEIH","PSCH","BK4584","FRTY","LABU","LU1983299246.USD","TECB","TBXU","BK4596","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671505252","title":"Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671505252","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671505252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:00","pubTimestamp":1790625600,"startTime":"0","endTime":"0","summary":"DEGEVMA is now FDA-approved across all indications of the reference product, Xgeva (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3370248/0/en/teva-continues-biosimilar-momentum-with-u-s-fda-approval-of-degevma-denosumab-adet-a-biosimilar-to-xgeva-denosumab.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4156","BK4588","MVF","BBP","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":18,"totalSize":421,"code":"91000000","status":"200"}]}}